Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy
- Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy is
- Diagnosed with a malignant solid tumor and scheduled to receive first course of
cytotoxic chemotherapy with cisplatin administered as a single I.V. dose of equal or
more than 70 mg/m2 over 1-4 hours on study Day 1, either alone or in combination with
other chemotherapeutic agents.
- If scheduled to receive combination regimens, non-cisplatin agents of moderate to
high emetogenic potential are allowed and they must be administered following the
cisplatin infusion and completed no more than 6 hours after the initiation of
- If scheduled to receive chemotherapy agents of minimal to low emetogenic potential,
they are to be given on Day 1 following cisplatin or on any subsequent study day.
- ECOG Performance Status of 0, 1, or 2
- Female patients of either non-childbearing potential or child-bearing potential with
a commitment to use contraceptive methods throughout the clinical trial
- Hematologic and metabolic status adequate for receiving a highly emetogenic
cisplatin-based regimen based on laboratory criteria (Neutrophils,Platelets,
Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance)
- If a patient has a known hepatic or renal impairment, he/she may be enrolled in this
study at the discretion of the Investigator.
- If a patient has a known history or predisposition to cardiac conduction interval
abnormalities he/she may be enrolled in this study at the discretion of the
- If female, pregnant or lactating.
- Current use of illicit drugs or current evidence of alcohol abuse.
- Scheduled to receive moderately emetogenic chemotherapy (MEC) or HEC from Day 2 to
Day 5 following cisplatin administration.
- Received or is scheduled to receive radiation therapy to the abdomen, or the pelvis
within 1 week prior to Day 1 or between Days 1 to 5.
- Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.
- Symptomatic primary or metastatic CNS malignancy.
- Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial
pressure, hypercalcemia, an active infection or any uncontrolled medical conditions
(other than malignancy) that, in the opinion of the investigator, may confound the
results of the study, represent another potential etiology for emesis and nausea
(other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks
in administering the study drugs to the patient.
- Known hypersensitivity or contraindication to 5-HT3 receptor antagonists (e.g.,
palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron) or
- Participation in a clinical trial involving palonosetron.
- Any investigational drugs (other than those given in this study) taken within 4 weeks
prior to Day 1, and/or is scheduled to receive any investigational drug during the
- Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1. However
topical and inhaled corticosteroids with a steroid dose of £ 10 mg of prednisone
daily or its equivalent are permitted.
- Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.
- Any medication with known or potential antiemetic activity within 24 hours prior to